Journal article
Metal-based drugs that break the rules.
- Allardyce CS Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. paul.dyson@epfl.ch.
- Dyson PJ
- 2016-01-29
Published in:
- Dalton transactions (Cambridge, England : 2003). - 2016
English
Cisplatin and other platinum compounds have had a huge impact in the treatment of cancers and are applied in the majority of anticancer chemotherapeutic regimens. The success of these compounds has biased the approaches used to discover new metal-based anticancer drugs. In this perspective we highlight compounds that are apparently incompatible with the more classical (platinum-derived) concepts employed in the development of metal-based anticancer drugs, with respect to both compound design and the approaches used to validate their utility. Possible design approaches for the future are also suggested.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1039/c5dt03919c
- PMID 26820398
- Persistent URL
- https://sonar.ch/global/documents/10117
Statistics
Document views: 33
File downloads: